Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.870
-0.140 (-6.97%)
At close: May 16, 2025, 4:00 PM
1.832
-0.038 (-2.05%)
After-hours: May 16, 2025, 7:57 PM EDT
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$2,040,682
Market Cap
57.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SKYE News
- 3 days ago - Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - GlobeNewsWire
- 7 days ago - Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity - GlobeNewsWire
- 10 days ago - Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 - GlobeNewsWire
- 18 days ago - Skye Bioscience to Participate in May Investment and Medical Conferences - GlobeNewsWire
- 4 weeks ago - A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
- 4 weeks ago - Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga